Table 3.
Multivariate logistic regression model for predictors of CUD.
| Variable |
Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |
| Robotic vs open | 1.15 (0.96–1.38) | 1.15 | 0.98 (0.80–1.19) | 0.80 |
| Year of diagnosis | ||||
| 2004 | Reference | Reference | ||
| 2005 | 1.17 (0.85–1.61) | 0.33 | N/A | |
| 2006 | 0.96 (0.70–1.34) | 0.83 | N/A | |
| 2007 | 1.10 (0.81–1.49) | 0.54 | N/A | |
| 2008 | 0.94 (0.70–1.26) | 0.68 | N/A | |
| 2009 | 0.87 (0.65–1.17) | 0.36 | N/A | |
| 2010 | 0.55 (0.40–0.77) | <0.001 | 0.45 (0.36–0.56) | <0.001 |
| 2011 | 0.66 (0.48–0.92) | 0.01 | 0.69 (0.56–0.85) | <0.001 |
| 2012 | 0.57 (0.41–0.79) | <0.001 | 0.83 (0.67–1.02) | 0.07 |
| 2013 | 0.58 (0.42–0.80) | <0.001 | 0.92 (0.74–1.13) | 0.40 |
| 2014 | 0.41 (0.29–0.58) | <0.001 | 1.01 (0.82–1.24) | 0.92 |
| 2015 | 0.48 (0.34–0.67) | <0.001 | N/A | |
| Sex | ||||
| Female | Reference | Reference | ||
| Male | 2.25 (1.89–2.69) | <0.001 | 1.18 (1.01–1.39) | 0.038 |
| Age group, years | ||||
| <60 | Reference | Reference | ||
| 60–69 | 0.57 (0.49–0.65) | <0.001 | 0.98 (0.81–1.19) | 0.84 |
| 70–79 | 0.29 (0.25–0.34) | <0.001 | 0.89 (0.72–1.11) | 0.29 |
| ≥80 | 0.17 (0.12–0.22) | <0.001 | 0.87 (0.67–1.12) | 0.27 |
| Ethnicity | ||||
| Non-Hispanic | Reference | |||
| Hispanic | 1.16 (0.81–1.65) | 0.42 | ||
| Charlson–Deyo Comorbidity Index | ||||
| 0 | Reference | Reference | ||
| ≥1 | 0.67 (0.57–0.77) | <0.001 | 0.89 (0.78–1.02) | 0.10 |
| Payer | ||||
| Private insurance | Reference | Reference | ||
| Not insured | 0.70 (0.49–1.00) | 0.05 | 0.79 (0.51–1.23) | 0.29 |
| Medicaid | 0.70 (0.53–0.92) | 0.01 | 1.01 (0.75–1.37) | 0.92 |
| Medicare | 0.35 (0.31–0.40) | <0.001 | 0.99 (0.84–1.17) | 0.88 |
| Other Government | 0.75 (0.43–1.29) | 0.30 | 1.02 (0.58–1.81) | 0.94 |
| N/A | 0.56 (0.33–0.95) | 0.03 | 0.71 (0.38–1.35) | 0.29 |
| Income, $ | ||||
| <38000 | Reference | Reference | ||
| 38000–47999 | 1.14 (0.93–1.40) | 0.22 | 1.11 (0.89–1.39) | 0.33 |
| 48000–62999 | 1.22 (0.99–1.48) | 0.06 | 1.09 (0.86–1.38) | 0.45 |
| ≥63000 | 1.45 (1.19–1.76) | <0.001 | 1.30 (1.00–1.68) | 0.047 |
| Education | ||||
| ≥21% | Reference | Reference | ||
| <7% | 1.27 (1.04–1.55) | 0.02 | 0.99 (0.75–1.30) | 0.92 |
| 13–20.9% | 1.07 (0.87–1.31) | 0.51 | 0.90 (0.72–1.12) | 0.34 |
| 7–12.9% | 1.06 (0.88–1.29) | 0.53 | 0.94 (0.74–1.19) | 0.59 |
| Facility type | ||||
| Community | Reference | Reference | ||
| Comprehensive | 0.88 (0.68–1.13) | 0.31 | 1.12 (0.79–1.58) | 0.52 |
| Academic/research | 1.02 (0.80–1.30) | 0.90 | 1.74 (1.25–2.42) | 0.001 |
| Integrated network | 0.61 (0.43–0.85) | <0.001 | 1.22 (0.83–1.79) | 0.31 |
| NAC | 1.04 (0.89–1.22) | 0.61 | ||
| Variant histology | ||||
| Pure urothelial | Reference | Reference | ||
| Urothelial with micropapillary component | 1.14 (0.67–1.92) | 0.63 | 0.89 (0.55–1.44) | 0.63 |
| Neuroendocrine tumour | 1.43 (0.93–2.18) | 0.10 | 1.01 (0.62–1.65) | 0.96 |
| Sarcomatoid | 0.86 (0.53–1.40) | 0.55 | 0.62 (0.37–1.03) | 0.064 |
| Squamous | 0.56 (0.38–0.84) | <0.001 | 0.63 (0.43–0.92) | 0.01 |
| Adenocarcinoma | 0.95 (0.47–1.94) | 0.90 | 1.18 (0.57–2.46) | 0.65 |
| T Stage | ||||
| T2 | Reference | Reference | ||
| T3 | 0.71 (0.58–0.86) | <0.001 | 0.82 (0.67–1.01) | 0.057 |
| T4 | 0.74 (0.59–0.92) | 0.01 | 0.78 (0.61–0.98) | 0.03 |
| N Stage | ||||
| 0 | Reference | |||
| 1 | 0.98 (0.71–1.35) | 0.90 | ||
| N2–N3 | 0.86 (0.61–1.20) | 0.38 | ||